Compare Invitation Homes Inc. Common Stock (INVH) vs Spyre Therapeutics Inc. Common Stock (SYRE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Invitation Homes Inc. Common Stock vs Spyre Therapeutics Inc. Common Stock — how do they compare? Invitation Homes Inc. Common Stock trades at $26.54 (market cap $15.70B), while Spyre Therapeutics Inc. Common Stock trades at $78.63 (market cap $7.52B). The key difference: Invitation Homes Inc. Common Stock is far larger — about 2.1× Spyre Therapeutics Inc. Common Stock's market cap, and Invitation Homes Inc. Common Stock pays a 4.51% dividend while Spyre Therapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Invitation Homes Inc. Common Stock for 0 Days and Spyre Therapeutics Inc. Common Stock for 0 Days on average.
| INVH | SYRE | |
|---|---|---|
Market Cap | $15.70B | $7.52B |
Volume | 4,685,416 | 1,441,031 |
Sector | Real Estate | Health |
52-Week High | $30.59 | $108.92 |
52-Week Low | $24.39 | $22.18 |
Typical Hold Time | 0 Days | 0 Days |
Enterprise Value | $24.16B | $6.52B |
Dividend Yield | 4.51% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
INVH trades at $26.59, down 0.41% on the day, with neutral technical signals and strong fundamental performance. The company has beaten earnings estimates for three consecutive quarters, with Q3 2026 results expected soon. Revenue growth from $2.73B in 2025 to $2.9B projected for 2026 supports a solid profit margin expansion to 23.13%. Analyst consensus remains bullish with a $31.67 price target, representing 19% upside potential from current levels.
The investment case centers on INVH's consistent earnings outperformance and robust single-family rental demand, though rising interest rates pose headwinds. With 56% of analysts recommending Buy and institutional accumulation continuing, the stock offers value at current levels despite technical consolidation. Key risks include interest rate sensitivity and regulatory changes affecting institutional homebuying.
SYRE trades at $80.45, down 6.34% over 24 hours, with technical indicators showing neutral momentum near key support at $79. The clinical-stage biotech shows no revenue but maintains strong analyst support (92% buy rating) with a $119.89 consensus target. Recent positive SPY003 phase II ulcerative colitis data (Zacks, 2026-09-09) and a $350 million public offering (GlobeNewsWire, 2026-10-05) provide catalysts, though financials reflect pre-revenue challenges with a -197.71% net margin.
Investment outlook balances high-risk, high-reward potential. The robust pipeline in inflammatory bowel disease offers substantial upside if clinical successes continue, but the absence of revenue, negative cash flow from operations, and reliance on financing pose significant risks. Near-term price action will hinge on Q3 2026 earnings and further clinical updates.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Invitation Homes Inc. Common Stock
Invitation Homes Inc. is a real estate investment trust that acquires, renovates, and leases single-family rental homes across roughly 19 US markets concentrated in Western and Southeastern US. It manages its portfolio through a pod-based local operating model supported by a maintenance technology platform.
Read more on INVH →About Spyre Therapeutics Inc. Common Stock
Spyre Therapeutics develops extended half-life antibody therapies for inflammatory bowel disease, including ulcerative colitis and Crohn's disease. Its pipeline targets pathways such as α4β7, TL1A, and IL-23 with antibodies engineered for infrequent subcutaneous dosing and potential combination use.
Read more on SYRE →
